Significance of Shift from Single Gene Testing to Multiplex Testing

Significance of Shift from Single Gene Testing to Multiplex Testing

Survivorship2017

2 years
659 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Junne Kamihara, MD, PhD of Dana-Farber Cancer Institute explains the significance of the shift from single gene testing to multiplex testing.This was recorded at ASCO's 2017 Cancer Survivorship Symposium in San Diego, CA.
Up Next Autoplay
Surgical Trial for RCC @CleClinicMD
Surgical Trial for RCC @CleClinicMD
Category: Kidney Cancer
0 Views
Cleveland Clinic 3 minutes
Phase 1/2 AUGMENT-101 Trial @sloan_kettering
Phase 1/2 AUGMENT-101 Trial @sloan_kettering
Category: Acute Lymphoblastic Leukemia
0 Views
Memorial Sloan Kettering 58 minutes
Do We Still Need The P-Value? @MDAndersonNews
Do We Still Need The P-Value? @MDAndersonNews
Category: Kidney Cancer
6 Views
kidneycancer 21 hours
Circulating Tumor DNA (ctDNA) Results in 110 Patients with Advanced Clear Cell Renal Cell Carcinoma
Circulating Tumor DNA (ctDNA) Results in 110 Patients with Advanced Clear Cell Renal Cell Carcinoma
Category: Kidney Cancer
7 Views
kidneycancer 22 hours
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Category: Non-Hodgkin Lymphoma
1 Views
Cancer-News 23 hours
Importance of Paradigms for Precision Medicine @sloan_kettering
Importance of Paradigms for Precision Medicine @sloan_kettering
Category: News
0 Views
Memorial Sloan Kettering 23 hours
Precision Medicine in Epichaperome Cancer Therapy @sloan_kettering
Precision Medicine in Epichaperome Cancer Therapy @sloan_kettering
Category: News
2 Views
Memorial Sloan Kettering 1 day
Myovant Sciences reports 97% Response rate in Phase 3 HERO Once-Daily Study, Oral Relugolix in Advanced Prostate Cancer Men
Myovant Sciences reports 97% Response rate in Phase 3 HERO Once-Daily Study, Oral Relugolix in Advanced Prostate Cancer Men
Category: Prostate Cancer
7 Views
Cancer-News 1 day
Anti–PD-1/PD-L1 Antibody Immunotherapy: Will This Affect Clinicians Today?
Anti–PD-1/PD-L1 Antibody Immunotherapy: Will This Affect Clinicians Today?
Category: Immunotherapy
4 Views
Cleveland Clinic 1 day
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
Category: Non-Small Cell Lung Cancer
1 Views
Cancer-News 1 day